Brentuximab vedotin
- Generic Name
- Brentuximab vedotin
- Brand Names
- Adcetris
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 914088-09-8
- Unique Ingredient Identifier
- 7XL5ISS668
- Background
Brentuximab vedotin, also known as Adcetrisยฎ, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug labe...
- Indication
Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin's lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or ...
- Associated Conditions
- CD30-expressing Mycosis Fungoides (MF), Classical Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma (PTCL), Primary Cutaneous Anaplastic Large Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Stage 3 Classical Hodgkin's Lymphoma
- Associated Therapies
- -
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-02-16
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT01534078
- Locations
- ๐บ๐ธ
Massachusetts General Hosptial, Boston, Massachusetts, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01492088
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
- Conditions
- Interventions
- Drug: brentuximab vedotinDrug: doxorubicin hydrochlorideDrug: vinblastineDrug: dacarbazineProcedure: quality-of-life assessmentGenetic: DNA analysisGenetic: RNA analysisRadiation: fludeoxyglucose F 18Procedure: positron emission tomographyOther: laboratory biomarker analysisOther: immunohistochemistry staining methodGenetic: polymorphism analysis
- First Posted Date
- 2011-11-22
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 48
- Registration Number
- NCT01476410
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
๐บ๐ธStanford University Medical Center, Stanford, California, United States
๐บ๐ธMemorial Sloan- Kettering Cancer Center, New York, New York, United States
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
- Conditions
- Interventions
- First Posted Date
- 2011-10-28
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT01461538
- Locations
- ๐บ๐ธ
Mayo Clinic Cancer Center, Jacksonville, Florida, United States
๐บ๐ธOcala Oncology Center, Ocala, Florida, United States
๐บ๐ธNorthwest Cancer Specialists, P.C., Tulatin, Oregon, United States
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-08-23
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT01421667
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
๐บ๐ธStanford Cancer Center, Stanford, California, United States
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level
- Conditions
- Interventions
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Youn Kim
- Target Recruit Count
- 36
- Registration Number
- NCT01396070
- Locations
- ๐บ๐ธ
Stanford University School of Medicine, Stanford, California, United States
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 57
- Registration Number
- NCT01393717
- Locations
- ๐บ๐ธ
City of Hope Medical Center, Duarte, California, United States
๐บ๐ธWeill Medical College, Cornell University, New York, New York, United States
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2017-06-28
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01309789
- Locations
- ๐บ๐ธ
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
๐บ๐ธCity of Hope National Medical Center, Duarte, California, United States
๐บ๐ธStanford Cancer Center, Stanford, California, United States
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Seagen Inc.
- Registration Number
- NCT01196208
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
๐ง๐ฌSpecializirana bolnica aktivno lechenie detsa ohcohematologichni zabolyavania Hematologichno, Sofia, Bulgaria
๐ต๐ฑCentrum Onkologii Institut im. Marii Sklodowskiej-Curie, Warsaw, Poland
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
- First Posted Date
- 2010-04-09
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 329
- Registration Number
- NCT01100502
- Locations
- ๐บ๐ธ
Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States
๐บ๐ธCleveland Clinic, The, Cleveland, Ohio, United States
๐บ๐ธWestern Pennsylvania Cancer Institute, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.